echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Youhe Medicine's CD40 in the treatment of advanced solid tumors in China completed the first patient medication in the Phase I clinical study

    Youhe Medicine's CD40 in the treatment of advanced solid tumors in China completed the first patient medication in the Phase I clinical study

    • Last Update: 2021-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 8, Youhe Pharmaceutical, a wholly-owned subsidiary of Biocytometer, announced on September 7 that its CD40 (YH003) China Phase I clinical study number was YH003003 and completed the first patient medication


    This study is a multi-center, open-ended, phase I dose escalation study evaluating the safety, tolerability and pharmacokinetics of YH003 in patients with advanced solid tumors


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.